Nightstar Therapeutics nightstarx.com


Public list: Smart Money VCs (6327) Pharma Startups (6570) Eye Health (703) Rare Diseases (230)

Nightstar Therapeutics (NASDAQ: NITE) is a clinical-stage gene therapy company focused on developing and commercializing one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy.

Nightstar Therapeutics (NASDAQ: NITE) is a clinical-stage gene therapy company focused on developing and commercializing one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigme...Show all

Company (Acquired)

Phone: +44-(0)20-7611-2031

Fax:

215 Euston Road

London, NW1 2BE
England, United Kingdom

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Nightstar Therapeutics $100M Jun 7, 2019

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Nightstar Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors

Competitors

Company Status Description Investors

Audentes Therapeutics

San Francisco, California, United States
IPO / Went publicAudentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).Login to see details

Patents

Title Application Date Patent Date Status
(Patent / Application)